Table of Contents

doi : 10.1016/S0923-7534(25)00822-1

Volume 36, Issue 8, August 2025, Pages i-ii

خرید پکیج و مشاهده آنلاین مقاله

Editorial Board

doi : 10.1016/S0923-7534(25)00823-3

خرید پکیج و مشاهده آنلاین مقاله

From the desert to the savannah, the future of combined MET-EGFR treatment

doi : 10.1016/j.annonc.2025.05.538

خرید پکیج و مشاهده آنلاین مقاله

The next-generation of nectin-4 targeted therapies

doi : 10.1016/j.annonc.2025.06.002

خرید پکیج و مشاهده آنلاین مقاله

Maintenance treatment in sarcomas: who is it for?

doi : 10.1016/j.annonc.2025.05.002

خرید پکیج و مشاهده آنلاین مقاله

Breast cancer germline multigene panel testing in mainstream oncology based on clinical–public health utility: ESMO Precision Oncology Working Group recommendations

doi : 10.1016/j.annonc.2025.04.012

خرید پکیج و مشاهده آنلاین مقاله

ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)

doi : 10.1016/j.annonc.2025.04.006

خرید پکیج و مشاهده آنلاین مقاله

Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis

doi : 10.1016/j.annonc.2025.04.001

خرید پکیج و مشاهده آنلاین مقاله

Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study

doi : 10.1016/j.annonc.2025.04.003

خرید پکیج و مشاهده آنلاین مقاله

Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study

doi : 10.1016/j.annonc.2025.04.009

خرید پکیج و مشاهده آنلاین مقاله

Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial☆

doi : 10.1016/j.annonc.2025.03.024

خرید پکیج و مشاهده آنلاین مقاله

Association of gene variant type and location with breast cancer risk in the general population

doi : 10.1016/j.annonc.2025.04.010

خرید پکیج و مشاهده آنلاین مقاله

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study☆

doi : 10.1016/j.annonc.2025.05.008

خرید پکیج و مشاهده آنلاین مقاله

Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study☆

doi : 10.1016/j.annonc.2025.05.007

خرید پکیج و مشاهده آنلاین مقاله

Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa

doi : 10.1016/j.annonc.2025.04.005

خرید پکیج و مشاهده آنلاین مقاله

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2− breast cancer and residual disease after neoadjuvant chemotherapy

doi : 10.1016/j.annonc.2025.05.531

خرید پکیج و مشاهده آنلاین مقاله

Reply to Letter to the Editor “Final results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2− breast cancer and residual disease after neoadjuvant chemotherapy—PENELOPE-B� by Sahin and Guven

doi : 10.1016/j.annonc.2025.04.007

خرید پکیج و مشاهده آنلاین مقاله

The unjustified fear of erdafitinib-induced central serous retinopathy

doi : 10.1016/j.annonc.2025.04.002

خرید پکیج و مشاهده آنلاین مقاله